Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
PharmaCyte Biotech Moving Closer to Human Clinical Trials
Around an Elite New Leadership Team
One of the untold stories regarding the recent transformation of PharmaCyte Biotech (OTCQB – PMCB - $0.1649 – Spec Buy) is that much of it is owed to the new leadership team. In the span of just over a year, Chief Executive Officer Kenneth L. Waggoner has significantly upgraded the quality of the Company’s leadership team, particularly with respect to the clinical research and execution side, which is a veritable “Who’s Who” in the global scientific community.
For example, the Company recently announced that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York, where he engineered his group's 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals. Having a former Big Pharma executive, especially one with M&A experience, is a huge “get” for a company of PharmaCyte Biotech’s size. Moreover, since many mid-stage biotechs end up as targets or actual acquisitions of Big Pharma, Mr. Liquard’s experience in understanding how to help build a company for growth and for possible sale are invaluable.
Diabetes
Virtually every member of PharmaCyte Biotech’s 16-member strong international Diabetes Consortium are noted experts in the field of diabetes research in Europe and Asia and their work has been published in top scientific journals. For example, Prof. Ann. M Simpson and her colleagues at the UTS developed the Melligen cell line which recently demonstrated in animal tests that it could reverse Type 1 diabetes.
PharmaCyte Biotech’s collaboration with the Diabetes Consortium will be critical to the future treatment of diabetes, as the next phase of tests for this cell line will include the use PharmaCyte Biotech’s Cell-in-a-Box® delivery system in order to ensure the viability and success of the cell line inside humans. PharmaCyte Biotech has an exclusive world-wide license to that cell line. When the Melligen cells are encapsulated using PharmaCyte Biotech signature platform technology, “Cell-in-a-Box®”, the world may see a break-through technology on how insulin-dependent diabetes is treated.
Cancer
The officers of PharmaCyte Biotech and Dr. Matthias Lohr, head of the Scientific Advisory Board, also have impressive resumes in the scientific field. COO Dr. Gerald W. Crabtree served as project manager for the development of the anticancer agent, Taxol® while Dr. Löhr and Dr. Walter Günzburg, the Company’s Chief Scientific Officer, were instrumental in the development of and clinical investigation of the earlier clinical trials of the combination of the Cell-in-a-Box® live cell encapsulation technology and the anticancer prodrug ifosfamide for the treatment of advanced pancreatic cancer. Both serve as consultants to PharmaCyte Biotech, as does the co-developer of the technology, Dr. Brian Salmons. Dr. Salmons is also a member of the Scientific Advisory Board.
The group of scientists associated with the PharmaCyte Biotech on the oncology side also boasts a past President of the American Association for Cancer Research who is also the leading authority on pancreatic cancer. In fact, Dr. Daniel Van Hoff, along with his team at Translational Drug Development (TD2), has conducted early clinical investigations of many of anti-cancer agents that have been approved by the FDA and that are in use today. Considering that Translational Drug Development (TD2) has been conducting a series of preclinical studies using the Company’s flagship technology in recent months, it illustrates the merit and potentially huge value inherent in PharmaCyte Biotech’s technology.
Clearly, the strength and depth of this team, along with the officers of the Company, have significantly enhanced the potential clinical success and future of PharmaCyte Biotech and the Company should start seeing the fruit of its labors and its team’s efforts in the near future.
For more information, refer to our previous sponsored PMCB Reports, Updates and Hot Topic Articles by visiting http://www.GoldmanResearch.com/
Senior Analyst: Robert Goldman
Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
Disclaimer
This Microcap Hot Topics Article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $7500 for a research subscription service and a series of articles. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. Goldman Small Cap Research relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
A Goldman Small Cap Research report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com
